The Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to recent news item captioned Trump Tariff News Live: GSK and AstraZeneca among top companies told to 'cut US prices or else'. The response from the Company is attached.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The BSE and NSE asked AstraZeneca Pharma India to clarify a MoneyControl news item headlined 'Trump Tariff News Live: GSK and AstraZeneca among top companies told to cut US prices or else.' The company clarified that (a) no negotiations were taking place in relation to the article, (b) it is not aware of any undisclosed information that could materially impact its share price, and (c) there are no regulatory or legal proceedings on this matter. Importantly, the company stated that the news item does not pertain to AstraZeneca Pharma India Limited (the Indian listed entity) and likely refers to its global parent AstraZeneca. No financial figures or material impact details were disclosed.
This clarification removes short-term uncertainty for retail investors — the US pricing pressure story relates to the global parent, not the Indian listed subsidiary, and the company confirms no direct exposure or undisclosed developments. Stock price reaction should be neutral, as the clarification addresses the misinformation rather than introducing new information.